ORAGRAFIN CALCIUM
LOE ApproachingNDAORALGRANULEPriority Review
Approved
Mar 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAGRAFIN CALCIUM is an oral granule diagnostic agent approved by Bracco in 1962 for radiographic imaging applications. The product is a calcium-based contrast medium administered orally to visualize gastrointestinal anatomy and pathology. It represents a legacy diagnostic modality in an era of advanced cross-sectional imaging.
LOE Approaching
With competitive pressure at 30% and approaching loss of exclusivity, the brand team is likely in defensive/maintenance mode with minimal expansion investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORAGRAFIN CALCIUM offers limited career growth given the LOE timeline and zero linked job openings. Roles are primarily focused on protecting remaining market share and maintaining compliance rather than innovation or expansion.
Product ManagerSales Representative
Worked on ORAGRAFIN CALCIUM at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.